The current research focus for cancer diagonosis is classical genetics, named "driving genes". However, not all cancer patients have typical genetic alterations, especially at early stage. In the past dacades, accumulating evidences have revealed that more than 80% diseases are closely related to epigenetic changes. The normally silenced copy of imprinted genes are reactivated at early stage of cancers, and finally proceed to copy number variation. This study will screen for a panel of imprinted genes and build quantitative models to assist the diagnosis of multiple cancers.
Study Type
OBSERVATIONAL
Enrollment
1,500
The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGSensitivity of imprinting cancer early detection
Number of patients "declared positive" with the imprinting early detection among the patients suffered from cancer
Time frame: In the middle of the study, an average of 15 months
Specificity of imprinting cancer early detection
Number of patients "declared negative" with the imprinting early detection among the patients who are with benign tumors or other diseases
Time frame: In the middle of the study, an average of 15 months
Comparison of the sensitivity of the imprinting detection versus cytopathology
Number of patients "declared positive" with the imprinting early detection versus patients "declared positive" with the cytopathology
Time frame: In the middle of the study, an average of 15 months
Comparison of the specificity of the imprinting detection versus cytopathology
Number of patients "declared negative" with the imprinting early detection versus patients "declared negative" with the cytopathology
Time frame: In the middle of the study, an average of 15 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.